{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T11:24:50Z","timestamp":1761218690245,"version":"3.41.2"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006546","name":"Angelini Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006546","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>Depressive disorders are leading contributors to the global mental health-related burden, and they represent a challenge for real-world clinicians, due to the low rates of remission despite the high availability of treatments. Often, depression shows in the context of multiple chronic comorbidities, thus requiring precise and accurate management of pharmacological treatments to avoid interactions and side effects. These criticalities call for the need for new strategies of treatment, which may include new insights into the pharmacological properties of currently available antidepressant drugs, to enhance their efficacy in the different contexts in which depression may arise. Trazodone is the prototype serotonin antagonist\/reuptake inhibitor antidepressant (SARI). Due to the malleability granted by its multiple formulations, trazodone is frequently used to treat depression, both as an add-on to other antidepressants and as a monotherapy, with satisfying results. Moreover, its tolerability makes it one of the most prescribed antidepressants in patients with poly-treated comorbid medical illnesses, especially in the elderly. Herein, a case series is presented regarding the use of trazodone in patients with complex comorbid diagnoses or distressing side effects. Each of the three cases has been discussed in three specific Round Tables, involving expert clinicians in the fields of Psychiatry, Neurology, General Practice, and Geriatrics using the Nominal Group Technique. The ideas collected have been used to integrate the cases and the discussion with the intent of facilitating accessibility to the widest audience of physicians and clinical workers in different clinical practice contexts. The final aim of this paper is to promote an increasingly personalized use of trazodone in real-world patients with depression.<\/jats:p>","DOI":"10.3389\/fpsyt.2024.1362221","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T12:36:04Z","timestamp":1724934964000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case report: Personalizing the use of trazodone in real-world patients: a study of three cases of depression with comorbidities"],"prefix":"10.3389","volume":"15","author":[{"given":"Gianluca","family":"Rosso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Benatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Pettorruso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaia","family":"Sampogna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmine","family":"Tomasetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,29]]},"reference":[{"key":"B1","unstructured":"Global Burden of Disease Study 2019 (GBD 2019) Data Resources | GHDx"},{"key":"B2","unstructured":"Depression and Other Common Mental Disorders"},{"key":"B3","unstructured":"Rapporto salute mentale. Analisi dei dati del Sistema Informativo per la Salute Mentale (SISM). Anno 2022\n            Di CesareM\n            MagliocchiettiN\n            RomanelliM\n            SantoriE\n          2023"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31948-2","article-title":"Depression","volume":"392","author":"Mahli","year":"2018","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"crossref","DOI":"10.4103\/0019-5359.16261","article-title":"Diagnosis of depression in general practice","volume":"59","author":"Sengupta","year":"2005","journal-title":"Indian J Med Sci"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-013-0448-6","article-title":"Depressive syndromes in neurological disorders","volume":"263","author":"Hellmann-Regen","year":"2013","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.V67N0912","article-title":"Realistic expectations and a disease management model for depressed patients with persistent symptoms","volume":"67","author":"Keitner","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"B8","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2147\/NDT.S198774","article-title":"Management of treatment-resistant depression: challenges and strategies","volume":"16","author":"Voineskos","year":"2020","journal-title":"Neuropsychiatr Dis Treat"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/wps.21142","article-title":"Understanding depression beyond the \u201cmind-body\u201d dichotomy","volume":"22","author":"Maj","year":"2023","journal-title":"World Psychiatry"},{"key":"B10","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/WPS.20771","article-title":"The clinical characterization of the adult patient with depression aimed at personalization of management","volume":"19","author":"Maj","year":"2020","journal-title":"World Psychiatry"},{"key":"B11","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1176\/APPI.AJP.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am J Psychiatry"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.5498\/wjp.v5.i4.366","article-title":"Treating comorbid anxiety and depression: Psychosocial and pharmacological approaches","volume":"5","author":"Coplan","year":"2015","journal-title":"World J Psychiatry"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1017\/s1092852900024020","article-title":"Mechanism of action of trazodone: a multifunctional drug","volume":"14","author":"Stahl","year":"2009","journal-title":"CNS Spectr"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-012-0010-5","article-title":"Rediscovering trazodone for the treatment of major depressive disorder","volume":"26","author":"Fagiolini","year":"2012","journal-title":"CNS Drugs"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet"},{"key":"B16","first-page":"20","article-title":"Extended-release trazodone in major depressive disorder: A randomized, double-blind, placebo-controlled study","volume":"6","author":"Sheehan","year":"2009","journal-title":"Psychiatry (Edgmont)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S399948","article-title":"Long-term treatment with trazodone once-A-day (TzOAD) in patients with MDD: an observational, prospective study","volume":"19","author":"Shrashimirova","year":"2023","journal-title":"Neuropsychiatr Dis Treat"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/FPSYT.2023.1207621","article-title":"Treating depression in clinical practice: new insights on the multidisciplinary use of trazodone","volume":"14","author":"Albert","year":"2023","journal-title":"Front Psychiatry"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/J.GENHOSPPSYCH.2014.10.010","article-title":"Antidepressant-induced sexual dysfunction during treatment with fluoxetine, sertraline and trazodone; a randomized controlled trial","volume":"37","author":"Khazaie","year":"2015","journal-title":"Gen Hosp Psychiatry"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.36150\/2499-6564-N320","article-title":"Trazodone: a multifunctional antidepressant. Evaluation of its properties and real-world use","volume":"69","author":"Cuomo","year":"2021","journal-title":"J OF GERONTOLOGY AND GERIATRICS"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/BRAINSCI13010086\/S1","article-title":"TED\u2014Trazodone efficacy in depression: A naturalistic study on the efficacy of trazodone in an extended-release formulation compared to SSRIs in patients with a depressive episode\u2014Preliminary report","volume":"13","author":"Siwek","year":"2023","journal-title":"Brain Sci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852921000304","article-title":"Early response to trazodone once-a-day in major depressive disorder: review of the clinical data and putative mechanism for faster onset of action","volume":"26","author":"Albert","year":"2021","journal-title":"CNS Spectr"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1159\/000492079","article-title":"Once-a-day trazodone in the treatment of depression in routine clinical practice","volume":"102","author":"\u010ce\u0161kov\u00e1","year":"2018","journal-title":"Pharmacology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/S11096-016-0257-X\/FIGURES\/2","article-title":"How to use the nominal group and Delphi techniques","volume":"38","author":"McMillan","year":"2016","journal-title":"Int J Clin Pharm"},{"article-title":"Diagnostic and statistical manual of mental disorders 5th ed., text rev","volume-title":"American Psychiatric Association.","year":"2022","key":"B25"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X21666230403080624","article-title":"Update on pharmacological treatment for comorbid major depressive and alcohol use disorders: the role of extended-release trazodone","volume":"21","author":"Di Nicola","year":"2023","journal-title":"Curr Neuropharmacol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/BF03035120","article-title":"Standardizing the Hamilton Depression Rating Scale: past, present, and future","author":"Williams","year":"2001","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/J.PSYCHRES.2020.112788","article-title":"A comparison of the dimensionality of the Hamilton Rating Scale for anxiety and the DSM-5 Anxious-Distress Specifier Interview","volume":"284","author":"Rodriguez-Seijas","year":"2020","journal-title":"Psychiatry Res"},{"key":"B29","first-page":"28","article-title":"The clinical global impressions scale: applying a research tool in clinical practice","volume":"4","author":"Busner","year":"2007","journal-title":"Psychiatry (Edgmont)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/SJ.IJIR.3900472","article-title":"Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction","volume":"11","author":"Rosen","year":"1999","journal-title":"Int J Impot Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/J.AJP.2022.103417","article-title":"Global prevalence of depression in older adults: A systematic review and meta-analysis of epidemiological surveys","volume":"80","author":"Cai","year":"2023","journal-title":"Asian J Psychiatr"},{"key":"B32","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/EPIREV\/MXS004","article-title":"The dynamic relationship between physical function and cognition in longitudinal aging cohorts","volume":"35","author":"Clouston","year":"2013","journal-title":"Epidemiol Rev"},{"key":"B33","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1097\/JGP.0B013E3181F17F0A","article-title":"Patterns of alcohol and drug use among depressed older adults seeking outpatient psychiatric services","volume":"19","author":"Satre","year":"2011","journal-title":"Am J Geriatr Psychiatry"},{"key":"B34","doi-asserted-by":"publisher","first-page":"923","DOI":"10.3233\/JAD-181106","article-title":"Treatment of alzheimer\u2019s disease: trazodone, sleep, serotonin, norepinephrine, and future directions","volume":"67","author":"Ashford","year":"2019","journal-title":"J Alzheimer\u2019s Dis"},{"key":"B35","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/S0924-9338(11)72201-5","article-title":"P01-490 - Trazodone in elderly patients with dementia: impact on caregiver burden","volume":"26","author":"P\u00e9rez","year":"2011","journal-title":"Eur Psychiatry"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1007\/S00228-021-03161-6","article-title":"The effects of trazodone on human cognition: a systematic review","volume":"77","author":"Gon\u00e7alo","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1185\/03007999009111497","article-title":"Efficacy and tolerability of controlled-release trazodone in depression: a large multicentre study in general practice","volume":"12","author":"Moon","year":"1990","journal-title":"Curr Med Res Opin"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/CTS.13253","article-title":"Estimation of brain receptor occupancy for trazodone immediate release and once a day formulations","volume":"15","author":"Oggianu","year":"2022","journal-title":"Clin Transl Sci"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1708\/3202.31796","article-title":"Clinical guidance for the use of trazodone in major depressive disorder and concomitant conditions: pharmacology and clinical practice","volume":"54","author":"Cuomo","year":"2019","journal-title":"Riv Psichiatr"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.9740\/MHC.2016.07.191","article-title":"Sexual dysfunction in selective serotonin reuptake inhibitors (SSRIs) and potential solutions: A narrative literature review","volume":"6","author":"Jing","year":"2016","journal-title":"Ment Health Clin"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/J.1365-2850.2006.01001.X","article-title":"Iatrogenic sexual dysfunction and the protective withholding of information: in whose best interest","volume":"13","author":"Higgins","year":"2006","journal-title":"J Psychiatr Ment Health Nurs"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.3390\/JCM8101640","article-title":"Management strategies for antidepressant-related sexual dysfunction: A clinical approach","volume":"8","author":"Montejo","year":"2019","journal-title":"J Clin Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"128","DOI":"10.4103\/0976-500X.81913","article-title":"Sexual dysfunction with the use of antidepressants in a tertiary care mental health setting \u2013 a retrospective case series","volume":"2","author":"Lahon","year":"2011","journal-title":"J Pharmacol Pharmacother"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0B013E31816D1CDC","article-title":"Trazodone for the treatment of sexual dysfunction induced by serotonin reuptake inhibitors: a preliminary open-label study","volume":"32","author":"Stryjer","year":"2009","journal-title":"Clin Neuropharmacol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/J.JCMA.2013.05.002","article-title":"A nationwide population study of trazodone use in urology patients","volume":"76","author":"Cheng","year":"2013","journal-title":"J Chin Med Assoc"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/BS.IRN.2017.05.024","article-title":"Depression and anxiety in parkinson\u2019s disease","volume":"133","author":"Schrag","year":"2017","journal-title":"Int Rev Neurobiol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1176\/JNP.15.1.74","article-title":"The contribution of somatic symptoms to the diagnosis of depressive disorder in Parkinson\u2019s disease: a discriminant analytic approach","volume":"15","author":"Leentjens","year":"2003","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/MDS.20397","article-title":"Long-term efficacy and safety of pramipexole in advanced Parkinson\u2019s disease: results from a European multicenter trial","volume":"20","author":"M\u00f6ller","year":"2005","journal-title":"Mov Disord"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1136\/JNNP.53.7.597","article-title":"Cognitive impairments and depression in Parkinson\u2019s disease: a follow up study","volume":"53","author":"Starkstein","year":"1990","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/S00702-017-1830-8","article-title":"Trazodone alleviates both dyskinesia and psychosis in the parkinsonian marmoset model of Parkinson\u2019s disease","volume":"125","author":"Hamadjida","year":"2018","journal-title":"J Neural Transm (Vienna)"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1590\/S0004-282X2009000300007","article-title":"The use of an antagonist 5-HT2a\/c for depression and motor function in Parkinson\u2019 disease","volume":"67","author":"Werneck","year":"2009","journal-title":"Arq Neuropsiquiatr"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0B013E3181EE7F63","article-title":"Trazodone for the treatment of neuroleptic-induced acute akathisia: a placebo-controlled, double-blind, crossover study","volume":"33","author":"Stryjer","year":"2010","journal-title":"Clin Neuropharmacol"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2024.1362221\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T12:36:14Z","timestamp":1724934974000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2024.1362221\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,29]]},"references-count":52,"alternative-id":["10.3389\/fpsyt.2024.1362221"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2024.1362221","relation":{},"ISSN":["1664-0640"],"issn-type":[{"type":"electronic","value":"1664-0640"}],"subject":[],"published":{"date-parts":[[2024,8,29]]},"article-number":"1362221"}}